deltatrials
Completed PHASE3 INTERVENTIONAL 2-arm NCT03020303

Aldosterone bloCkade for Health Improvement EValuation in End-stage Renal Disease (ACHIEVE)

Sponsor: Canadian Institutes of Health Research (CIHR)

Conditions Endstage Renal Disease
Interventions Placebo Oral Tablet Spironolactone 25Mg Tablet
Updated 20 times since 2017 Last updated: Mar 17, 2025 Started: Jul 7, 2017 Primary completion: Mar 14, 2025 Completion: Mar 14, 2025
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT03020303, this PHASE3 trial focuses on Endstage Renal Disease and remains completed. Sponsored by Canadian Institutes of Health Research (CIHR), it has been updated 20 times since 2017, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Feb 2017 – ~Jun 2017 · 4 months · monthly snapshot~Jun 2017 – ~Aug 2017 · 2 months · monthly snapshot~Aug 2017 – ~Feb 2018 · 6 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Dec 2018 · 6 months · monthly snapshot~Dec 2018 – ~Mar 2019 · 3 months · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Sep 2019 · 3 months · monthly snapshot~Sep 2019 – ~Nov 2019 · 2 months · monthly snapshot~Nov 2019 – ~Nov 2020 · 12 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Sep 2022 · 20 months · monthly snapshot~Sep 2022 – ~Mar 2023 · 6 months · monthly snapshot~Mar 2023 – ~Jul 2024 · 16 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Oct 2024 · 30 days · monthly snapshot~Oct 2024 – ~Apr 2025 · 6 months · monthly snapshot~Apr 2025 – ~Jun 2025 · 2 months · monthly snapshot~Jun 2025 – ~Sep 2025 · 3 months · monthly snapshot~Sep 2025 – present · 10 months · monthly snapshot

Change History

20 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Jun 2025 — Sep 2025 [monthly]

    Completed PHASE3

  3. Apr 2025 — Jun 2025 [monthly]

    Completed PHASE3

    Status: Recruiting → Completed

  4. Oct 2024 — Apr 2025 [monthly]

    Recruiting PHASE3

  5. Sep 2024 — Oct 2024 [monthly]

    Recruiting PHASE3

▶ Show 15 earlier versions

  1. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE3

  2. Mar 2023 — Jul 2024 [monthly]

    Recruiting PHASE3

  3. Sep 2022 — Mar 2023 [monthly]

    Recruiting PHASE3

  4. Jan 2021 — Sep 2022 [monthly]

    Recruiting PHASE3

  5. Nov 2020 — Jan 2021 [monthly]

    Recruiting PHASE3

  6. Nov 2019 — Nov 2020 [monthly]

    Recruiting PHASE3

  7. Sep 2019 — Nov 2019 [monthly]

    Recruiting PHASE3

  8. Jun 2019 — Sep 2019 [monthly]

    Recruiting PHASE3

  9. Mar 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  10. Dec 2018 — Mar 2019 [monthly]

    Recruiting PHASE3

  11. Jun 2018 — Dec 2018 [monthly]

    Recruiting PHASE3

  12. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE3

  13. Aug 2017 — Feb 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet Recruiting → Recruiting

  14. Jun 2017 — Aug 2017 [monthly]

    Not Yet Recruiting PHASE3

  15. Feb 2017 — Jun 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Canadian Institutes of Health Research (CIHR)
  • Population Health Research Institute
Data source: Population Health Research Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aberdeen, United Kingdom , Ankara, Turkey (Türkiye) , Bairro Santa Teresa, Brazil , Bangalore, India , Baotou, China , Beijing, China , Bela Vista, Brazil , Belfast, United Kingdom , Belo Horizonte, Brazil , Bengaluru, India and 109 more locations